Published in Expert Opin Med Diagn on January 01, 2009
Tumour response of osteosarcoma to neoadjuvant chemotherapy evaluated by magnetic resonance imaging as prognostic factor for outcome. Int Orthop (2014) 1.98
Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy. Pharmacogenomics J (2011) 1.05
The prognostic significance of CD44V6, CDH11, and β-catenin expression in patients with osteosarcoma. Biomed Res Int (2013) 0.90
Upregulation of the miR-17-92 cluster and its two paraloga in osteosarcoma - reasons and consequences. Genes Cancer (2014) 0.88
CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients. Oncotarget (2011) 0.87
Structuring osteosarcoma knowledge: an osteosarcoma-gene association database based on literature mining and manual annotation. Database (Oxford) (2014) 0.83
Genomic heterogeneity of osteosarcoma - shift from single candidates to functional modules. PLoS One (2015) 0.82
KiSS1 inhibits growth and invasion of osteosarcoma cells through inhibition of the MAPK pathway. Eur J Histochem (2013) 0.80
Tumor self-seeding by circulating tumor cells in nude mouse models of human osteosarcoma and a preliminary study of its mechanisms. J Cancer Res Clin Oncol (2013) 0.79
Prognostic role of CD44 expression in osteosarcoma: evidence from six studies. Diagn Pathol (2014) 0.79
Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma. Oncol Lett (2015) 0.76
Protein kinase C epsilon and genetic networks in osteosarcoma metastasis. Cancers (Basel) (2013) 0.75
Lack of association between bcl-2 expression and prognosis of osteosarcoma: a meta-analysis. Int J Clin Exp Med (2015) 0.75
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 16.68
A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature (1986) 13.96
Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol (2008) 11.05
Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev (1993) 7.40
Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science (1987) 6.93
Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med (1969) 6.54
A cancer family syndrome in twenty-four kindreds. Cancer Res (1988) 6.39
p53 ubiquitination: Mdm2 and beyond. Mol Cell (2006) 5.57
IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res (1998) 5.41
Structural variants: changing the landscape of chromosomes and design of disease studies. Hum Mol Genet (2006) 4.60
Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome. Nat Genet (1999) 4.56
The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med (2004) 4.28
Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med (1995) 4.11
The Fas signaling pathway: more than a paradigm. Science (2002) 3.45
Role of chemokines in tumor growth. Cancer Lett (2007) 3.36
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol (2008) 3.34
Biology and therapeutic advances for pediatric osteosarcoma. Oncologist (2004) 3.34
Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer (2006) 3.11
Ezrin, a key component in tumor metastasis. Trends Mol Med (2004) 2.89
Telomeres: cancer to human aging. Annu Rev Cell Dev Biol (2006) 2.88
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst (2007) 2.85
p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol (2005) 2.78
Telomere dysfunction increases mutation rate and genomic instability. Cell (2001) 2.62
Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci U S A (1985) 2.44
Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res (2005) 2.31
Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem (1996) 2.23
Current treatment of osteosarcoma. Cancer Invest (2001) 2.20
Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet (2001) 2.19
Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol (2000) 2.15
Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res (2001) 2.10
A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol (2007) 2.07
MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst (1994) 2.06
Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene (2002) 1.96
Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res (2004) 1.93
Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol (2003) 1.87
Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst (2003) 1.83
Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol (1998) 1.81
Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol (2007) 1.81
Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo. Mol Cell Biol (2001) 1.78
Rothmund-Thomson syndrome due to RECQ4 helicase mutations: report and clinical and molecular comparisons with Bloom syndrome and Werner syndrome. Am J Med Genet (2000) 1.72
SnapShot: Wnt/beta-catenin signaling. Cell (2007) 1.71
Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol (2007) 1.70
Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res (1994) 1.66
Rothmund-thomson syndrome responsible gene, RECQL4: genomic structure and products. Genomics (1999) 1.65
Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis (2007) 1.63
An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res (2005) 1.60
Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer (2004) 1.58
Studies of the RB1 gene and the p53 gene in human osteosarcomas. Pediatr Hematol Oncol (1992) 1.57
Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer (2005) 1.55
High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer (2003) 1.52
The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol (2003) 1.51
Etiology of osteosarcoma. Clin Orthop Relat Res (2002) 1.50
TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol (2005) 1.50
Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res (2005) 1.49
Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer (2004) 1.48
Roles of Wnt signalling in bone growth, remodelling, skeletal disorders and fracture repair. J Cell Physiol (2008) 1.47
CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol (2006) 1.42
Biology of osteogenic sarcoma. Cancer J (2005) 1.42
Some retinoblastomas, osteosarcomas, and soft tissue sarcomas may share a common etiology. Proc Natl Acad Sci U S A (1988) 1.41
Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer (2004) 1.40
Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol (1999) 1.39
Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res (2005) 1.37
Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res (2003) 1.36
Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res (2004) 1.35
Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer (2004) 1.34
Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. Cancer Res (1995) 1.34
Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clin Exp Metastasis (2003) 1.32
Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res (2005) 1.32
Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene (2001) 1.29
Metastatic osteosarcoma. Cancer (2006) 1.27
Orthopedic surgery options for the treatment of primary osteosarcoma. Cancer Control (2008) 1.26
Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer (2004) 1.24
Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation. Cell Cycle (2005) 1.23
Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol (2003) 1.20
Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol (1996) 1.19
Telomere maintenance and cancer -- look, no telomerase. Nat Rev Cancer (2002) 1.17
Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma. Med Pediatr Oncol (1998) 1.17
Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res (2007) 1.16
DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma. Int J Cancer (1999) 1.15
ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer (2002) 1.14
Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep (2002) 1.14
Comparative genomic hybridization analysis of human sarcomas: II. Identification of novel amplicons at 6p and 17p in osteosarcomas. Genes Chromosomes Cancer (1995) 1.14
Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer (2005) 1.14
Chromosomal regions involved in the pathogenesis of osteosarcomas. Genes Chromosomes Cancer (2000) 1.13
Analysis of genes critical for growth regulation identifies Insulin-like Growth Factor 2 Receptor variations with possible functional significance as risk factors for osteosarcoma. Cancer Epidemiol Biomarkers Prev (2007) 1.13
Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res (2004) 1.12
Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis. Clin Cancer Res (2004) 1.11
Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res (2007) 1.11
p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer (1997) 1.09
The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer (2003) 1.08
Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol (2004) 1.07
Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol (2005) 1.05
Involvement of the retinoblastoma gene in primary osteosarcomas and other bone and soft-tissue tumors. Clin Orthop Relat Res (1991) 1.05
The proteome profile of the human osteosarcoma U2OS cell line. Cancer Genomics Proteomics (2008) 1.05
Li-Fraumeni syndrome: a p53 family affair. Cell Cycle (2005) 1.05
Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res (2005) 1.18
Three novel mutations in SQSTM1 identified in familial Paget's disease of bone. J Bone Miner Res (2003) 1.08
Somatic mutations in SQSTM1 detected in affected tissues from patients with sporadic Paget's disease of bone. J Bone Miner Res (2009) 0.94
Analysis of environmental factors in familial versus sporadic Paget's disease of bone--the New England Registry for Paget's Disease of Bone. J Bone Miner Res (2003) 0.86
Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma. Int J Cancer (2003) 0.84
Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. J Bone Miner Res (2003) 0.84
An adaptive strategy for single- and multi-cluster gene assignment. Biotechnol Prog (2003) 0.75